Comparative Benchmarking
In the context of the broader market, PHAR competes directly with industry leaders such as SPRY and ESPR. With a market capitalization of $917.42M, it holds a leading position in the sector. When comparing efficiency, PHAR's gross margin of N/A stands against SPRY's 72.29% and ESPR's 56.84%. Such benchmarking helps identify whether Pharming Group NV is trading at a premium or discount relative to its financial performance.
